1063
11. Cassidy, J. Textbook of pediatric rheumatology [Text]/ J. Cassidy, R. Petty. – New York:
Churchill Livingstone, 2002. – 125 p.
12. Deighton, C. Management of rheumatoid arthritis: summary of NICE guidance [Text] / C.
Deighton, R. O’Mahony, J. Tosh et al. // BMJ. –2007. -
№
38. –P. 702.
13. Feldman, M. Role of cytokines in rheumatoid arthritis [Text] / M. Feldman, F. Brennan, R. N.
Maini // Immunology. – 1996. -
№
14. - 39- 44.
14. Hashkes, P. J. Medical treatment of juvenile idiopathic arthritis [Text] / P. J. Hashkes, R. M.
Laxer // JAMA. – 2005. -
№
294. –P. 1671-1684.
15. Lee, D.M. Rheumatoid arthritis [Text] / D.M. Lee,M. E.Weinblatt // Lancet.- 2001. -
№
358. –
P. 903- 911.
16. Horneff, G.Medical treatment of juvenile idiopathic arthritis [Text] / G. Horneff, S. Augustin //
Med.Monatsschr. Pharm. – 2008. -
№
31. –P.326- 336.
17. Lovell, D.J. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis [Text] /
D. J. Lovell, N. Ruperto, S. Goodman// NEngl JMed. - 2008. -
№
359. - P. 810–820.
18. Lovell, D. J., Ruperto, N., Cuttica, R. et al. Randomized trial of infliximab for the treatment of
polyarticular juvenile rheumatoid arthritis [Poster]// American College of Rheumatology 68
th
Annual ScientificMeeting. SanAntonioOctober 16-21, 2004. ––Poster 523.
19.Medley, S.E.J How safe is starting high dose methotrexate? [Abstract]/ S. E. J.Medley, A. L.
Dolan, G. Coakley // Ann. Rheum. Dis. - 68(Suppl. 3). – 2007. - P. 591.
20.Mery, P. Comparison of methotrexate monotherapy with a combination of methotrexate and
etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised,
double-blind, parallel treatment trial [Text] / F. C.Breedveld, S. Hall et al.// Lancet. – 2008. -
№
372. –P. 375–382.
21. O’Dell, J. Treating rheumatoid arthritis early: window of opportunity? [Text]/ J. O’Dell//
ArthritisRheum. - 2002 -
№
46. –P.283-285.
22. Rantalaiho, V. The good initial response to therapy with a combination of traditional disease-
modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish
rheumatoid arthritis combination therapy [Text] / V.Rantalaiho,M. Korpela, P. Hannonen et all.
// ArthritisRheum. - 2009. -
№
60. –P. 1222–1231.
23. Ravelli, A. Juvenile idiopathic arthritis [Text]/ A. Ravelli, A.Martini // Lancet. – 2007. -
№
369.
–P. 767-778.
24. Saag, K. Recommendation for the use of nonbiologic and biologic disease- modifying
antirheumatic drugs in rheumatoid arthritis [Text]/ K. Saag, G. Teng, N. Patkar et American
College ofRheumatology// ArthritisRheum. - 2008. –
№
59. - P. 762- 784.
25. Schett, G. Review: Immune cells and mediators of inflammatory arthritis [Text] //
Autoimmunity. – 2008. -
№
41. –P.224-229.
26. Smolen, J. S.Treating rheumatoid arthritis to target: recommendations of an international task
force [Text]/ J. Smolen, D. Aletaha, J.W. J. Bijlsma et al. // Ann. Rheum. Dis. – 2010. -
№
69. -
P. 631–637.
27. Smolen, J.S. Therapeutic strategies in early rheumatoid arthritis [Text]/ J. S. Smolen, D.
Aletaha, K. P.Machold // Best Pract. Res. Clin. Rheumatol. – 2005. -
№
19(1). - P.163–177.
28. Smolen, J. Prediction of joint damage in patient with early rheumatoid treated with high- dose
metotrexate with or without concomitant adalimumab: results from the ASPIRE [Text] / J.
Smolen, D. Van der Heijde, E. St. Clair E. et al. // ArthritisRheum. - 2006. -
№
54 (3). - P. 702-
710.
29.
vanVollenhoven, R.F. Treatment of rheumatoid arthritis: state of the art 2009 [Text] / R. F. van
Vollenhoven // Nat. Rev. Rheumatol. – 2009. -
№
5. –P.531–541.
30.
Weinblatt, M.E. Adalimumab, for the treatment of rheumatoid arthritis in patients taking
concomitant methotrexate the ARMADA trial [Text] / M. E. Weinblatt, E. C. Keystone, D. E.
Furst et al. // ArthritisRheum. - 2003. -
№
48. –P. 35–45.
